Skip to main content

Table 7 28-day mortality (safety population)

From: A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock

  AZD9773 cohort 1
(50 U/kg)
(n= 8)
AZD9773 cohort 2
(250 U/kg)
(n= 9)
AZD9773 cohort 3
(250/50 U/kg) (n= 12)
AZD9773 cohort 4
(500/100 U/kg) (n= 10)
AZD9773 cohort 5
(750/250 U/kg)
(n= 8)
Placebo (n= 23)
Alive, n (%) 6 (75.0) 5 (55.6) 7 (58.3) 9 (90.0) 7 (87.5) 16 (69.6)
Dead, n (%) 2 (25.0) 4 (44.4) 5 (41.7) 1 (10.0) 1 (12.5) 6 (26.1)
Lost to follow-up, n (%) 0 0 0 0 0 1 (4.3)